Recombinant Activated Factor Vii
Intracerebral Hemorrhage
Joseph Broderick, MDPhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
39 Active assets in the Intracerebral Hemorrhage cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Edoxaban Population Health Research Institute | Phase 4 | BBB |
Tranexamic Acid Christian Medical College and Hospital, Ludhiana, India | Phase 4 | BB |
Acetylsalicylic Acid University Hospital, Lille | Phase 4 | BB |
Rivaroxaban Imperial College London | Phase 3 | BB |
Valproic Acid University of North Carolina, Chapel Hill | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Recombinant Activated Factor Vii is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →